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Background: Jugular venous reflux (JVR) has been reported to cause cough syncope via retrograde-transmitted
venous hypertension and consequently decreased cerebral blood flow (CBF). Unmatched frequencies of JVR and
cough syncope led us to postulate that there should be additional factors combined with JVR to exaggerate CBF
decrement during cough, leading to syncope. The present pilot study tested the hypothesis that JVR, in addition to
an increased level of plasma endothelin-1 (ET-1), a potent vasoconstrictor, is involved in the pathophysiology of
cough syncope.
Methods: Seventeen patients with cough syncope or pre-syncope (Mean[SD] = 74.63(12.37) years; 15 males) and
51 age/gender-matched controls received color-coded duplex ultrasonography for JVR determination and plasma
ET-1 level measurements.
Results: Multivariate logistic analysis showed that the presence of both-side JVR (odds ratio [OR] = 10.77, 95%
confident interval [CI] = 2.40-48.35, p = 0.0019) and plasma ET-1 > 3.43 pg/ml (OR = 14.57, 95% CI = 2.95-71.59,
p = 0.001) were independently associated with the presence of cough syncope/ pre-syncope respectively. There
was less incidence of cough syncope/ pre-syncope in subjects with the absence of both-side JVR and a plasma
ET-1 ≦3.43 pg/ml. Presence of both side JVR and plasma ET-1 level of > 3.43 pg/ml, increased risk for cough
syncope/pre-syncope (p < 0.001).
Conclusions: JVR and higher plasma levels of ET-1 are associated with cough syncope/ pre-syncope. Although
sample size of this study was small, we showed a synergistic effect between JVR and plasma ET-1 levels on the
occurrence of cough syncope/pre-syncope. Future studies should confirm our pilot findings.
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Syncope is defined as a transient loss of consciousness
with subsequent spontaneous recovery, resulting from
global cerebral hypoperfusion [1]. Besides syncope, a
lesser degree of compromised cerebral blood flow (CBF)
may lead to pre-syncope symptoms, such as wooziness,
light-headedness, nearly fainting sensation and/or vis-
ual dimming. Cough syncope refers to syncope upon* Correspondence: kyyang@vghtpe.gov.tw
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reproduction in any medium, provided the orcoughing, [2] the pathogenesis of which is unclear and
probably multifactorial.
Endothelin-1 (ET-1) is a potent vasoconstrictor pep-
tide derived from vascular endothelial cells [3]. Besides
its direct vasoconstriction effect, increased ET-1 levels
may result in decreased nitric oxide (NO) availability,
thereby predisposing to vasoconstriction [4,5]. ET-1 also
contributes to the regulation of cerebral vascular tone.
ET-1 levels have been shown as elevated in the plasma
and cerebrospinal fluid (CSF) of subarachnoid hemorrhage
(SAH) patients, with the presence of elevated ET-1 levels
correlating with the persistence of cerebral vasospasm
[4,6,7]. Additionally, ET-1 levels have been observed toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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administration of ET-1 antagonists prevents cerebral vaso-
spasm [8]. Therefore, ET-1 is one of determinants of CBF.
Endothelial dysfunction with imbalanced releases of NO
and ET-1 has also been recognized in chronic obstructive
pulmonary disease (COPD); those populations have been
found with more frequent cough syncope [9,10].
Jugular venous reflux (JVR) is found frequently in
transient global amnesia, [11] transient monocular blind-
ness patients, [12] and elderly people with more severe
age-related white matter changes [12]. JVR may occur
during a Valsalva maneuver (VM) or Valsalva-like activ-
ities, such as cough, when increased intrathoracic pres-
sure is beyond the competence of internal jugular
venous (IJV) valves. VM-induced JVR, which may retro-
gradely transmit venous hypertension into cerebral ven-
ous system, decreases cerebral perfusion pressure (CPP)
and consequently reduces CBF during Valsalva-like ac-
tivities [13-16]. It has been suggested that JVR plays a
role in the pathophysiology of cough syncope [17]. How-
ever, the low incidence of cough syncope, disproportion-
ate to the higher frequency of JVR, [18] implies that
additional factors should be involved. In the present
study, we hypothesized that (1) the presence of JVR is
associated with cough syncope, and (2) there is an inter-
active effect between JVR and the plasma ET-1 levels on
the occurrence of cough syncope.
Methods
Subjects
This was a prospective case–control pilot study. For
valid statistical analyses, the numbers of recruited cough
syncope/pre-syncope cases (case group) and age/gender-
matched controls (control group) were set as 1:3. Be-
tween July/2009 and August/2010, Taiwanese patients
consecutively enrolled at the Neurological and Chest
Outpatient Clinics of Taipei Veterans General Hospital
with cough syncope/pre-syncope were assessed for in-
clusion into this study. The definition of cough syncope
and cough pre-syncope were defined as the presence of
consciousness loss, and the presence of wooziness, light-
headedness, a nearly fainting sensation and/or visual
dimming without consciousness loss, respectively, dur-
ing involuntary coughing. Arterial blood pressure (ABP)
measurement, eletrocardiography (EKG), eletroencepha-
lography (EEG) and neck vascular duplex sonography
were performed in all patients. Subjects eligible for partici-
pation in the current study had normal EKG and EEG
studies, and the absence of neck arterial stenosis by duplex
sonography. Exclusion criteria (including the control
group) were a past history of stroke, ischemic heart dis-
ease, congestive heart disease, valvular heart disease,
cardiac arrhythmia, or malignancy. Upon recruiting one
eligible cough syncope/pre-syncope case, three age/gender-matched controls were recruited from patients
who visited the Chest Outpatient Clinic due to cough but
no cough-related neurological symptoms. The study proto-
col was approved by the Institutional Review Board of
Taipei Veterans General Hospital and was conducted in ac-
cordance with the Helsinki Declaration. Written informed
consent was obtained from all participants or their author-
ized representatives before enrollment.
Vascular risk factors were defined according to inter-
national guidelines [19]. COPD was diagnosed per the
definitions in the Global Initiative for Chronic Obstruct-
ive Lung Disease guidelines [20].JVR determination
Neck color-coded duplex sonography was performed in
all subjects with a 7-MHz linear transducer (Sonos 5500,
Hewlett Packard, Andover, MA, USA) by the same tech-
nician, who was blinded to subjects’ characteristics. The
examination was done at least 2 hours after a light
breakfast in the morning. On examination, subjects were
in a head-straight, flat supine position after a quiet 10
minute rest. The IJV was initially insonated longitudin-
ally and thoroughly from the proximal part of the neck
base rostrally to the distal part at the submandibular
level in order to detect any possible spontaneous JVR at
baseline [11]. Then, the VM was performed by forcible
expiration from subject’s mouth into a flexible rubber
tube connected to a manometer. Subjects were asked to
reach 40 mm Hg Valsalva pressure and maintain it for at
least 10 seconds. During the VM, the distal margin of
the window of the color signal was placed at the tip of
the flow divider of the internal carotid artery. The color
box was adjusted to include the entire lumen of the IJV;
if retrograde color appeared in the center of the lumen,
the retrograde flow would then be confirmed by Doppler
spectrum. JVR was determined when the retrograde-
flow color in the center of the lumen and the Doppler-
flow waveform demonstrated reversal of flow for more
than 0.5 seconds at baseline and/or during the VM
(Figure 1) [11,15,21,22].Plasma ET-1 levels measurement
Non-fasting venous blood samples were drawn before
neck color-coded duplex sonography in all subjects, at a
similar morning time to avoid a circadian variation and
collected in the tubes containing EDTA. Plasma was
separated from whole blood and stored at −80°C until
analysis. Plasma levels of ET-1 were measured using a
commercially available immunoassay kit (R&D Systems
Inc., Minneapolis, MN, USA). The intra- and interassay
coefficients of variation of ET-1 in our laboratory were
4.4% and 5.7%. All measurements were performed in
duplicate.
Figure 1 Retrograde flow detected by color duplex and in the
Doppler spectrum during Valsalva maneuver (VM) is
considered as jugular venous reflux (JVR).
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Since VM/cough-induced hypotension is presumed as
one possible mechanism in cough syncope, [23,24] we
also recorded ABP changes during the VM, a maneuver
that mimics the effect of cough, by servocontrolled in-
frared finger plethysmography (Finapres, model 2300,
Ohmeda Monitoring Systems, Englewood, CT, USA.) in
patients with cough syncope and age/gender-matched
controls. Experiments were performed in the morning at
least 2 hours after a light breakfast. After at least 10
minutes of supine rest, two VMs were performed with a
5-minute interval between them. The second VM was
used for data analysis. The VM was performed for a dur-
ation of 15 seconds, with intrathoracic pressure of 40
mmHg maintained and monitored by a pressure gauge
connected to a flexible tube.
Beat-to-beat ABP measured for 15 seconds before the
VM was averaged as baseline. Phasic changes in mean
ABP with the VM were defined previously [15,25]. There
are four distinct well described phases of ABP changes.
With the beginning of the strain (phase I), there is a
transient increase in ABP resulting from transmission of
intrathoracic pressure to the arterial system. At phase II,
continuously increased intrathoracic pressure will im-
pede venous return to the heart and lead to a fall in
ABP early in phase II (phase IIa). Then in late phase II
(phase IIb), a sympathetic response to the fall in ABP
will produce a rise in ABP. When the strain is relieved
(phase III), more venous blood volume pools in the
expanded intrathoracic veins due to sudden intrathor-
acic pressure decrement, which decreases left atrial fill-
ing and, subsequently, ABP. This is followed by an
overshoot in ABP (phase IV), when atrial filling is nor-
malized accompanied by remain-elevated sympathetictone. Relative changes in mean ABP at each phase of
the VM are calculated as the ratio of the magnitude of
the phasic changes at each phase divided by the base-
line measurements.
Statistical analysis
Continuous data are expressed as mean (SD). The non-
parametric Mann–Whitney U test was used to compare
the case group and the control group. The x2 test was
used for evaluating categorical variables, and Fisher’s
exact test was used for instances in which individual
counts in any group were fewer than five. Univariate and
multivariate logistic analyses were performed using odds
ratio (OR) with a 95% confidence interval (CI) to test
the independent effect of factors associated with cough
syncope/pre-syncope. To determine the predictive ac-
curacy of ET-1 level for cough syncope, receiver operat-
ing characteristic (ROC) curve was constructed, and the
area under the curve (AUC) was calculated. Based on
the optimal cut-off value of plasma ET-1 level deter-
mined from the ROC curve, in univariate and multivari-
ate analyses, we took 3.43 pg/ml as the cut-off point.
Among JVRs of different severities and sides, we used
the presence of both-side JVR to run the univariate and
multivariate analyses. To test the interactive effects
between JVR and the levels of plasma ET-1 on the pres-
ence of cough syncope/pre-syncope, we divided all
subjects into four groups. Those groups were (1) the
presence of both-side JVR with plasma ET-1 > 3.43 pg/ml;
(2) the absence of both-side JVR with plasma ET-1 >
3.43 pg/ml; (3) the presence of both-side JVR with
plasma ET-1 ≦3.43 pg/ml; and (4) the absence of both-
side JVR with plasma ET-1 ≦3.43 pg/ml. Then we used
Mantel-Haenszel x2 to test for trends across these four
groups in the frequency of cough syncope/pre-syncope.
For all tests, p < 0.05 was considered statistically signifi-
cant. All analyses were performed with SAS software,
version 9.1 (SAS Institute Inc, Cary, NC).
Results
Patient characteristics
All cough syncope/pre-syncope cases presented with first-
time, cough-related neurological symptoms. We excluded
one patient with severe internal carotid artery stenosis,
and another patient with seizure history. In the end, there
were 10 patients with cough syncope, 7 patients with
cough pre-syncope, and 51 age/gender-matched control
subjects recruited in the present study. In subjects with
cough pre-syncope, upon cough all had a nearly fainting
sensation (light-headedness, dizziness, etc.) and five
(71.43%) had visual dimming. All subjects in the case
group developed a neurological symptom during a pro-
longed or repetitive vigorous cough. They did not experi-
ence syncope/pre-syncope at other times. Subjects with
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and evidence of convulsion or incontinence during cough.
The demographic/clinical characteristics are demon-
strated in Table 1. The severity of COPD was similar be-
tween case and control groups. There were no significant
differences in the demographic factors between case and
control groups. In addition, there were no differences in
the demographic characteristics, the frequencies of JVR,
and plasma ET-1 levels between subjects with cough syn-
cope and cough pre-syncope (Mann–Whitney U and x2
test; data not shown).
JVR and plasma ET-1 level comparisons between cough
syncope/pre-syncope and control groups
The case group had higher frequencies of right-side, left-
side, and both-side JVR, respectively (Table 1), and also
higher plasma ET-1 levels (Figure 2) compared with con-
trol group. All JVRs detected in the case group occurred
during the VM. Five patients of the cough syncope
group and six of the cough pre-syncope group com-
plained of dizziness during the VM. In the normal
group, all right-side JVRs were detected during the VM,
whereas in the left-side JVR, two (11.11%) were shown
at baseline and 16 were detected during the VM.
The presence of JVR and higher plasma ET-1 levels
predicted the presence of cough syncope/pre-syncope
ROC curve plotted for studying the utility of plasma
ET-1 level in predicting cough syncope are shown in
Figure 3. The area under the ROC curve (AUC) for ET-1
was 0.8 (p < 0.001, 95% confidence interval 0.68 ~ 0.92).Table 1 The characteristics and the frequencies of jugular ven
syncope/pre-syncope patients and control subjects
Cough syncope/pre-syncope
Age, mean (SD), yr 74.63 (12.37)
Gender, M/F 15/2
Vascular risk factors, n (%)
HTN 4 (23.53%)




GOLD I 6 (43%)
GOLD II 6 (43%)
GOLD III 2 (14%)
Right-side JVR, n (%) 13 (76.47%)
Left-side JVR, n (%) 11 (64.71%)
Both-side JVR, n (%) 10 (58.82%)
Plasma ET-1 level, pg/ml 3.64 (1.23)
Abbreviations: HTN = hypertension; COPD = chronic obstructive pulmonary disease
JVR = jugular venous reflux; ET-1 = endothelin-1; SAH, subarachnoid hemorrhage.The optimal cut-off point of ET-1 for predicting cough
syncope was 3.43 pg/ml, with the sensitivity 0.59 and the
specificity 0.90. Multivariate logistic analysis (Table 2)
showed that the presence of both-side JVR and plasma
ET-1 > 3.43 pg/ml were two independent factors asso-
ciated with the presence of cough syncope/pre-syncope.
Table 3 shows an interactive effect between both-side JVR
and plasma levels of ET-1 on the occurrence of cough
syncope/pre-syncope. There was a significant tendency
that the presence of both-side JVR and plasma ET-1 >
3.43 pg/ml increased the frequency of cough syncope/
pre-syncope (p < 0.001). There was less incidence of
cough syncope/pre-syncope in subjects with the absence
of both-side JVR and a plasma ET-1 ≦3.43 pg/ml,
however, a significant increased trend of cough syncope/
pre-syncope was seen in subjects with the presence of
both-side JVR as well as a plasma ET-1 level > 3.43 pg/ml.
No difference of ABP changes during VM between
patients with cough syncope and normal controls
Ten patients with cough syncope [69.44(16.13) years; 9
males] and thirty age/gender-matched control subjects
[69.44(16.13) years; 27 males] received the beat-to-beat
ABP measurement at baseline and during the VM. The
baseline and each phase of mean ABP between these two
groups were similar [case group versus control group,
mmHg; baseline=74.65(12.40) versus 77.91(14.33), p =
0.525; phase I=90.40(14.91) versus 99.59(18.05), p = 0.155;
phase IIa=65.07(16.95) versus 73.61(17.43), p = 0.185;
phase IIb=78.77(19.17) versus 88.63(21.33), p = 0.203;
phase III=54.27(19.39) versus 62.58(17.80), p = 0.218;ous reflux and plasma endothelin-1 levels in cough















; GOLD = Global Initiative for Chronic Obstructive Lung Disease guideline;
Figure 2 Plasma endothelin-1 levels in cough-syncope group (n = 17) and control group (n = 51).
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There was also no difference in each phasic change
in mean ABP between case group and normal group
[case group versus control group, %; phase I=21.46
(7.87) versus 28.80(17.73), p = 0.216; phase IIa=−13.25
(16.58) versus −5.61(15.84), p = 0.199; phase IIb=5.56
(23.52) versus 14.08(23.64), p = 0.329; phase III=−27.88
(22.05) versus −19.31(20.93), p = 0.275; phase IV=11.76Figure 3 Receiver operator characteristic curve of the plasma endoth(17.49) versus 19.41(23.17), p = 0.346]. Three patients with
cough syncope complained of dizziness during the VM.
Discussion
This pilot study is the first to prove that JVR is asso-
ciated with cough syncope. Cough-induced JVR retro-
gradely transmits venous hypertension into the cerebral
venous system, increases cerebral venous pressure orelin-1 level in predicting cough syncope/pre-syncope patients.
Table 2 Univariate and multivariate logistic analysis of factors associated with cough syncope/pre-syncope
Univariate p value Multivariate p value
HTN 1.26 (0.34-4.71) 0.729
Diabetes mellitus 0.56 (0.06-5.30) 0.365
Hyperlipidemia 0.73 (0.63-0.85) 0.307
Smoking 0.79 (0.21-2.96) 0.729
Obesity 0.62 (0.12-3.21) 0.518
COPD 2.33 (0.59-9.24) 0.219
Both-side JVR 7.68 (2.25-26.16) 0.001 10.77 (2.40-48.35) 0.0019
Plasma ET-1 > 3.43 pg/ml 10.35 (2.75-38.98) 0.0006 14.57 (2.95-71.59) 0.0010
Presented as OR (95% CI). Abbreviations: HTN = hypertension; COPD = chronic obstructive pulmonary disease; JVR = jugular venous reflux; ET-1 = endothelin-1.
Table 3 Frequencies of cough syncope/pre-syncope in
four groups of subjects classified by the presence of





Cough syncope/pre-syncope p value
- +
No ≦ 3.43 38 (92.7%) 3 (7.3%) <0.001
Yes ≦ 3.43 8 (61.5%) 5 (38.5%)
No > 3.43 5 (55.6%) 4 (44.4%)
Yes > 3.43 0 5 (100%)
Presented as numbers (%). Abbreviations: JVR = jugular venous reflux; ET-1 =
endothelin-1.
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quently reduce CBF during cough [13-17]. There are
other known facts supporting the idea that increased
cerebral venous or intracranial pressure might play a
role in the pathophysiology of cough syncope [26,27].
One study measured IJV venous pressure during cough
in patients with cough syncope and found equalized IJV
venous pressure with ABP [26]. In this situation, the net
pressure gradient between ABP and venous pressure, the
CPP, would decrease and lead to reduced CBF. Another
study using transcranial Doppler (TCD) showed a cessa-
tion of forward flow in the cerebral artery and diastolic
flow reversal during cough-induced syncope [27]. This
hemodynamic finding during cough suggests increased
impedance in the downstream circulatory pathway, such
as in conditions with elevated cerebral venous pressure.
Another novel finding is that higher plasma levels of
ET-1 could predict the occurrence of cough syncope.
The plasma ET-1 levels have been recognized as a bio-
marker for predicting vascular endothelial dysfunction
[28]. Whether patients with cough syncope have impaired
cerebral endothelial function that makes them susceptible
to cerebral hypoperfusion is worthy of further study.
The prevalence of JVR shown in a large-population
study is around 20-40% [18]. If JVR contributes to the
pathophysiology, the question remains why only certain
people with JVR have developed cough syncope. There
might be different additional factors combining with JVR
involved in the pathophysiology of different diseases
which are found associated with JVR. Our previous study
has demonstrated an interactive effect between JVR and
aging on the severity of age-related white matter changes
[22]. We suggested that JVR adding age-related cerebral
vascular abnormalities precipitated cerebral hypoperfusion
in elderly people. In the present study, we have also found
that, besides JVR, elevated plasma ET-1 levels might play
an additional role in the pathophysiology of cough syn-
cope. This could explain the mismatch between the inci-
dence of cough syncope and VM-induced JVR.
Previous studies showed a fall in systemic ABP during
or at the end of coughing, or during the VM in patientswith cough syncope, and presumed cough-induced
hypotension might play a role in the mechanism
[23,24,29,30]. In our study, however, there was no sig-
nificant difference in mean ABP changes during and at
the end of the VM between case and control groups. It
is possible that, compared with a virtual cough, the VM
had a relatively insufficient intrathoracic elevation and
resulted in a non-significant ABP decrement during the
VM in the case group. Because of discrepant findings
between present and previously reported cough syncope
results, [23,24,29,30] we hypothesized that patients with
cough syncope might have a higher central venous or
intrathoracic pressure at baseline or/and during VM
and VM-like activities (e.g. cough), and may induce
vasovagal responses via baroreceptor stimulus during
cough more easily than people without cough syncope.
This could explain why people with cough syncope have
both cough-induced hypotension and higher frequency
of VM-induced JVR.
There are limitations in our pilot study. We enrolled
relatively small sample size (n = 17) and used post-hoc
data analysis approach. While simulating the pathophysi-
ology of cough syncope, we evaluated JVR in subjects
with supine position instead of upright position, and
used VM instead of a heavy cough. Additionally, CBF
changes were not analyzed in the present study. There-
fore, we could not demonstrate the relationship between
JVR/plasma ET-1 levels and CBF changes in our subjects
with cough syncope. However, our previous study using
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CBF [15].
Conclusions
JVR and higher plasma levels of ET-1 are associated with
cough syncope/pre-syncope. Although sample size of
this study was small, we showed a synergistic effect be-
tween JVR and plasma ET-1 levels on the occurrence of
cough syncope/pre-syncope. Future studies should con-
firm our pilot findings.
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